Ronald Sherman, DO
Pulmonary Disease · Escanaba, MINPI 1033191242
Payments from drug & device makers
Across 112 payments — averaging $229.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$16K
- Boehringer Ingelheim$5K
- GSK$4K
- AstraZeneca$396
- Sanofi$160
- Takeda Pharmaceuticals U.S.A., Inc.$135
- plus $42 from 3 others
What the payments were for
- Speaking & faculty fees$20,03578%
- Travel & lodging$3,96715%
- Food & beverage$1,6306%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 44 | $16,064 |
| Boehringer Ingelheim | 9 | $5,125 |
| GSK | 13 | $3,729 |
| AstraZeneca | 25 | $396 |
| Sanofi | 8 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $135 |
| United Therapeutics Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $12 |
| Insmed, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$15,258
- TRELEGY ELLIPTA$3,600
- OFEV$3,185
How this compares
$25,651 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 592 | $492,784 |
| OfevNintedanib Esylate | 15 | $189,714 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $125,338 |
| GlassiaAlpha-1-Proteinase Inhibitor | 15 | $123,949 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 141 | $104,578 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $80,427 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $54,897 |
| Dupixent SyringeDupilumab | 12 | $45,579 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $37,015 |
| Spiriva RespimatTiotropium Bromide | 52 | $32,823 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $24,438 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 84 | $19,866 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $19,049 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $17,287 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 404 | $14,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,729 | $647,157860 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $5,125 | $276,839154 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $396 | $129,016232 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $135 | $123,94915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Escanaba
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
- Yvonne HuangAnn Arbor$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.